Collegium Pharmaceutical, Inc. generated quarterly net revenues of $199.9 million, a 6% increase year-over-year. This growth reflects strong demand for its ADHD portfolio, particularly JORNAY PM, which saw a 41% revenue rise and could signal further investor confidence moving forward.

Key Highlights

  • The ADHD segment emerged as a standout performer, generating JORNAY PM revenues of $46.1 million, representing an impressive 41% increase year-over-year.
  • Collegium's overall product revenues reached $199.9 million, driven by strategic initiatives within its ADHD and pain portfolios.
  • Collegium Pharmaceutical shares are down 21.5% year-to-date, which reflects a period of adversity amid broader market volatility.

Collegium Pharmaceutical, Inc. (NASDAQ: COLL) reported quarterly net revenues of $199.9 million for the period ending June 30, 2026, reflecting a 6% increase from $188 million in the same quarter last year. The company outperformed Wall Street expectations with an adjusted earnings per share of $1.92, surpassing the consensus estimate of $1.75. This performance underscores the effective growth of its ADHD product offerings, marking a significant step in enhancing shareholder value amidst a challenging market backdrop.

Strong ADHD Portfolio Performance

The ADHD segment emerged as a standout performer, generating JORNAY PM revenues of $46.1 million, representing an impressive 41% increase year-over-year. The number of healthcare providers prescribing JORNAY PM hit a record high of over 30,000, a jump of 17.6% from the previous year. This growth was supported by a 13.1% year-over-year rise in new prescriptions, bolstering demand for the medication.

Furthermore, the acquisition of AZSTARYS, which brought in $12.9 million in revenue within a partial quarter, positions Collegium favorably ahead of the important back-to-school season. These factors illustrate a solid foundation for further market penetration, particularly as ADHD treatments gain traction in the minds of prescribers and patients alike.

Financial Performance Overview

Collegium's overall product revenues reached $199.9 million, driven by strategic initiatives within its ADHD and pain portfolios. Despite a decline in the pain segment, where revenues fell 9% year-over-year to $140.9 million, the solid performance in ADHD medications largely compensated for these losses. Nucynta franchise revenues notably decreased by 24% to $35.2 million, adding pressure to overall profitability.

Operating expenses also rose sharply to $106.6 million, a 45% surge compared to the previous year's quarter. This information highlights the balancing act the company faces as it invests in growth while managing rising costs.

Market Context and Future Guidance

Collegium Pharmaceutical shares are down 21.5% year-to-date, which reflects a period of adversity amid broader market volatility. The recent quarterly performance and strong growth in the ADHD segment suggest potential for a turnaround. The company has reaffirmed its full-year guidance, updating projected revenues for AZSTARYS to between $65 million and $75 million, while maintaining JORNAY PM revenue estimates at $190 million to $200 million.

Investors will closely monitor further developments, particularly upcoming conferences scheduled for September and how the company plans to navigate the remainder of the fiscal year.

Analysis based on the Form 8-K filed 6 August 2026; figures verified against the filing and live market data.

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.